STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] Ensysce Biosciences, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reported beneficial ownership of 74,711 shares of Ensysce Biosciences common stock, representing 3.15% of the company's outstanding shares based on 2,370,698 shares reported in the companys quarterly report. The position is held through Adage entities for which Adage acts as investment manager, and the filing shows shared voting and shared dispositive power over the reported shares rather than sole control.

The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. Because the disclosed stake is below 5%, the filing classifies the ownership as a non-control disclosure under Schedule 13G/A.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Adage disclosed a modest 3.15% stake (74,711 shares); disclosure signals transparency but is not a control position.

The filing documents a minority position held by Adage Capital Management and two principals with shared voting and dispositive power. The stake is calculated from an outstanding share base of 2,370,698 shares as reported in the companys quarterly report, producing the 3.15% figure. Because this is a Schedule 13G/A and the reporting persons certify the holdings are in the ordinary course and not intended to influence control, the near-term market or governance impact is limited. Investors should treat this as an informative ownership disclosure rather than a strategic shift in control.

TL;DR: Ownership is material enough to note but remains below the 5% reporting threshold for activist intent; classification indicates non-control.

The structure described shows Adage acting as investment manager for Adage Capital Partners, with Messrs. Atchinson and Gross identified as managing members of related entities that collectively hold the shares. The reporting of shared voting and shared dispositive authority is consistent with manager-led holdings. The certification that the position is held in the ordinary course and not for control purposes aligns with Schedule 13G treatment and implies routine investment management rather than activist engagement.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Adage Capital Management, L.P.
Signature:/s/ Robert Atchinson
Name/Title:By: Adage Capital Partners LLC, its General Partner, By: Robert Atchinson, its Managing Member
Date:08/12/2025
Robert Atchinson
Signature:/s/ Robert Atchinson
Name/Title:Robert Atchinson, individually
Date:08/12/2025
Phillip Gross
Signature:/s/ Phillip Gross
Name/Title:Phillip Gross, individually
Date:08/12/2025

FAQ

What stake did Adage report in Ensysce Biosciences (ENSC)?

The filing reports beneficial ownership of 74,711 shares, representing 3.15% of Ensysce's outstanding common stock (based on 2,370,698 shares outstanding as reported).

Who filed the Schedule 13G/A for ENSC?

The statement was filed by Adage Capital Management, L.P. and two individuals, Robert Atchinson and Phillip Gross, in their capacities related to Adage entities.

Does the filing indicate Adage seeks to influence control of Ensysce (ENSC)?

No. The filing includes a certification that the securities were acquired and are held in the ordinary course of business and are not held for the purpose of changing or influencing control of the issuer.

What voting and disposition rights are reported?

The filing reports 0 shares with sole voting/dispositive power and 74,711 shares with shared voting and shared dispositive power for each reporting person.

Is the reported position considered a 5% or greater stake under SEC thresholds?

No. The reported 3.15% ownership is below the 5% threshold referenced in Item 5 and therefore is characterized as ownership of 5 percent or less of the class.
Ensysce Biosciences Inc

NASDAQ:ENSC

ENSC Rankings

ENSC Latest News

ENSC Latest SEC Filings

ENSC Stock Data

5.91M
3.44M
0.35%
6.04%
12.62%
Biotechnology
Pharmaceutical Preparations
Link
United States
LA JOLLA